Over the past 12 months, Nasus Pharma insiders bought $61,809 of stock on the open market (24.45K shares) and made no open-market sales.
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Dan Benjamin Teleman | Chief Executive Officer | 163,541 | 0 | 163,541 | 100.0% | 22 Jun, 2026 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 17 Jun, 2026 | Dan Benjamin Teleman | Chief Executive Officer | Acquired P | 6,550 | $3.10 | $20.31K | 163,541 | Direct |
| 22 Apr, 2026 | Dan Benjamin Teleman | Chief Executive Officer | Acquired P | 2,900 | $3.76 | $10.90K | 156,991 | Direct |
| 31 Mar, 2026 | Dan Benjamin Teleman | Chief Executive Officer | Acquired P | 15,000 | $2.04 | $30.60K | 21,246 | Direct |